NCT07266337尚未招募1 期
Clinical Study on the Safety and Efficacy of CD19/BCMA CAR T-cell Therapy for Refractory Systemic Lupus Erythematosus
Chengdu Ucello Biotechnology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2025年12月10日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- the incidence rate of Dose limited toxicity (DLTs)
研究概览
简要总结
The purpose of this clinical trial is to learn if CD19/BCMA CAR-T works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the CD19/BCMA CAR-T cell product.
The main questions it aims to answer are:
- What CAR-T-related adverse events (AEs) occur within 3 months after the CAR-T cell infusion?
- Which dose level is the optimal biological dose (OBD)?
- What is the the changes of disease activity status, proportion of patients achieving DORIS remission, percentage of participants achieving maintenance of drug-free DORIS remission, proportion of patients achieving SRI-4 remission, percentage of participants achieving maintenance of LLDAS?
Participants will:
- Receive CD19/BCMA CAR-T cells infusion on Day 0.
- Be hospitalized for at least 7 days post-infusion for close safety monitoring and remain within 2 hours of the treatment facility for at least 28 days.
- Visit the clinic at Day 14, Day 28, month 3, month 6, month 9, month 12, month 18 and month 24 after CAR-T cells infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 65 years (inclusive), regardless of gender.
- •Definitive diagnosis of systemic lupus erythematosus (SLE) meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE
- •Treatment refractory: failed ≥ 2 Conventional SLE treatments for at least 3 months.
- •Disease activity assessed by SELENA-SLEDAI score ≥ 6 with at least one British Isles Lupus Assessment Group (BILAG)-2004 Class A (severe manifestation) or two Class B (moderate manifestation) organ scores (or both); OR SELENA-SLEDAI score ≥
- •Adequate function of major organs as follows:
- •Bone marrow function: a. Neutrophil count ≥ 1×10⁹/L (no colony-stimulating factor therapy within 2 weeks prior to testing, excluding neutropenia caused by SLE); b. Hemoglobin ≥ 60 g/L.
- •Liver function: Alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (excluding ALT elevation caused by SLE); Aspartate aminotransferase (AST) ≤ 3 × ULN (excluding AST elevation caused by SLE); Total bilirubin (TBIL) ≤ 1.5 × ULN (excluding TBIL elevation caused by SLE).
- •Renal function: Creatinine clearance rate (CrCl) ≥ 30 mL/minute (calculated by Cockcroft/Gault formula, excluding CrCl reduction caused by SLE).
- •Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; Prothrombin time (PT) ≤ 1.5 × ULN.
- •Cardiac function: Hemodynamically stable.
- •Female subjects of childbearing potential and male subjects whose partners are of childbearing potential must use medically approved contraceptive methods or abstain from sexual intercourse during the study treatment period and for at least 6 months after the end of study treatment. Female subjects of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) test within 7 days prior to study enrollment and must not be breastfeeding.
- •Voluntarily agrees to participate in the clinical study, signs the informed consent form (ICF), and demonstrates good compliance with study procedures and follow-up.
排除标准
- •History of severe drug allergies or atopic diathesis.
- •Presence or suspicion of uncontrolled or treatment-requiring fungal, bacterial, viral, or other infections.
- •Cardiac function insufficient to tolerate the study treatment.
- •Congenital immunoglobulin deficiency.
- •History of malignant tumors within the past 5 years.
- •End-stage renal failure.
- •Positive for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer above the lower limit of detection; positive for hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody; positive syphilis test.
- •History of mental illness or severe cognitive impairment.
- •Use of disease-modifying immunosuppressive agents within 5 half-lives or biological agents within 4 weeks prior to enrollment.
- •Pregnant females or females planning to become pregnant.
- •Other conditions deemed by the investigator to preclude study participation.
研究组 & 干预措施
CAR-T cells treatment
Experimental
干预措施: CD19/BCMA CAR T-cells (Drug)
结局指标
主要结局
the incidence rate of Dose limited toxicity (DLTs)
时间窗: Up to 28 days after CD19/BCMA CAR-T injection
the incidence rate of CAR-T-related adverse events
时间窗: up to 28 days after CD19/BCMA CAR-T injection
次要结局
- Systemic Lupus Erythematosus Disease Activity Index score(month 6, month 9, month 12, month18, month 24 post CAR-T injection)
- Proportion of patients achieving DORIS remission(month 6, month 9, month 12, month18, month 24 post CAR-T injection)
- Percentage of participants achieving maintenance of drug-free DORIS remission(month 6, month 9, month 12, month18, month 24 post CAR-T injection)
- Proportion of patients achieving SRI-4 remission(month 6, month 9, month 12, month18, month 24 post CAR-T injection)
- Percentage of participants achieving maintenance of LLDAS(month 6, month 9, month 12, month18, month 24 post CAR-T injection)
- British Isles Lupus Assessment Group 2004 score(month 6, month 9, month 12, month18, month 24 post CAR-T injection)
- Physician's Global Assessment score(month 6, month 9, month 12, month18, month 24 post CAR-T injection)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML (Acute Myeloïd Leukemia) expressing CD19.”2023-509212-29-01Centre Hospitalier Universitaire De Lille5
招募中
1 期
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous NephropathyNCT07266181The First Affiliated Hospital of Air Force Medicial University5
进行中（未招募）
1 期
抗 CD19 单链抗体嵌合抗原受体 T 细胞注射液治疗 B 细胞急性淋巴细胞白血病Ⅰ期临床研究CTR2021059118
招募中
1 期
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)NCT05474885iCell Gene Therapeutics15
进行中（未招募）
2 期
CAR-T-19 注射液治疗复发 / 难治 B 细胞急性淋巴细胞白血病的Ⅱ期临床研究CTR2023420650